Tao Peng

机构：Guangzhou University of Chinese Medicine, First Affiliated Hospital of GuangXi Medical University · ORCID：0000-0001-6133-7078

发表论文 270 篇 · 总被引 7041 次 · h-index 39

代表论文

• Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial (2025 · The Lancet · 被引 51)
• Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 20)
• HDAC/NF-κB signaling pathway mediates gut microbiota dysbiosis in rheumatoid arthritis: Intervention mechanisms of Fengshining decoction (2025 · Phytomedicine · 被引 13)
• The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis (2025 · BMC Cancer · 被引 10)
• HBV-induced N6 methyladenosine modification of PARP1 enhanced AFB1-related DNA damage and synergistically contribute to HCC (2025 · Ecotoxicology and Environmental Safety · 被引 7)
• Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study (2025 · Liver Cancer · 被引 6)